Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this live activity for a maximum of 3.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from CTI BioPharma and Incyte Corporation.
ASH: Advancing Polycythemia Vera and Myelofibrosis: An Expert Tumor Board Discussion
November 30, 2018
Lunch and registration: 12:30 PM – 1:30 PM
Marriott Marquis San Diego Marina
Lunch: Grand Ballroom 5-6
Meeting Room: Grand Ballroom 5-6
333 W. Harbor Drive
San Diego, CA 92101
Registration is complimentary, but seating is limited.
Your management of patients with myelofibrosis (MF) that occurs as a primary or a late occurrence in the evolution of essential thrombocythemia (ET) and polycythemia vera (PV) requires careful diagnosis and classification based on histology, molecular characteristics, and risk stratification. A great deal of translation research from bench to beside for emerging novel compounds that target the JAK-STAT pathway has resulted in the development and application of pathway-specific therapeutic strategies.
As the volume of evidence supporting the role of targeted therapies continues to accumulate, it is important for you to understand novel mechanistic approaches to targeting mediators of tumor-promoting inflammation, and to apply clinical data to the development of treatment paradigms that maximize outcomes for your patients. This includes efficacy considerations, as well as development of strategies to identify and mitigate predictable treatment-related adverse events in a timely fashion.
To help you optimize the management of your patients with PV and MF, this activity will bring together renowned international experts in myeloproliferative neoplasm (MPN) treatment and clinical research in an in-depth tumor board format, which will assess the clinical impact of recent and emerging trial data on the development of treatment paradigms. A series of case presentations will be discussed, with clinical trial data tightly integrated to illuminate MPN treatment decisions related to frontline-and-beyond therapies, sequencing, switching, and patient and disease characteristics. Future directions in the field will also be addressed and considered with regard to how recent developments and highly anticipated trials may shape care in the near future.
The program will give you the opportunity to reflect on best practices and your own clinical decisions to personalize care for your patients with PV and MF.
This educational program is directed toward hematologists, medical oncologists, and other oncology healthcare professionals interested in the latest advances in the treatment of patients with MPNs. Fellows, researchers, nurses, nurse practitioners, physician assistants, and other healthcare professionals interested in the diagnosis and treatment of patients with hematologic malignancies are also invited to attend.
After successful completion of this educational activity, you should be better prepared to:
- Describe the pathogenesis and molecular characteristics of MPNs that influence the development of novel therapeutics for MF and PV
- Discuss the current treatment landscape for MF and PV, and factors of why they share common therapies
- Evaluate clinical data on emerging agents and regimens to treat MF and PV and their implications in routine practice
- Develop an evidence-based treatment plan to improve outcomes in the treatment of MPNs
Acknowledgment of Commercial SupportThis activity is supported by educational grants from CTI BioPharma and Incyte Corporation.
Brady Lee Stein, MD
Associate Professor of Medicine
Feinberg School of Medicine
You must be logged in to PER to register for this meeting
Or Register for PER now